SCHEMBL8331920

SCHEMBL8331920

Cc1cccc(-c2ccnc3c(C(N)=O)cnn23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 1.00
MAP2K1 Q02750 1/20 0.73
CLK4 Q9HAZ1 1/20 0.73
DYRK1B Q9Y463 1/20 0.73
KDM4E B2RXH2 3/20 0.70
PIM1 P11309 5/20 0.52
GSK3A P49840 3/20 0.52
EPHA2 P29317 1/20 0.52
AKT1 P31749 1/20 0.52
PIM3 Q86V86 1/20 0.52
MAPK13 O15264 2/20 0.49
CDK1 P06493 1/20 0.49
MAPKAPK2 P49137 1/20 0.49
PLK1 P53350 1/20 0.49
AURKB Q96GD4 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LIMK1 P53667 2/20 0.47
NTRK1 P04629 1/20 0.47
BRAF P15056 3/20 0.47
MARK2 Q7KZI7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3176935 0.90 TLR8 (0.82) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL8336450 0.85 TLR8 (0.74) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL8335009 0.85 TLR8 (0.73) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL8338772 0.84 CLK4 (1.00) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL3155668 0.84 TLR8 (0.72) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL10336150 0.83 TLR8 (0.71) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL8435070 0.82 KDM4E (1.00) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL9729664 0.81 TLR8 (0.68) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL9728658 0.81 MAP2K1 (0.78) TLR8MAP2K1CLK4DYRK1BKDM4E
SCHEMBL9877202 0.80 TLR8 (0.67) TLR8MAP2K1CLK4DYRK1BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014092-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION AGS THERAPEUTICS SAS (FR) 2026-01-15 US claimed
WO-2024194423-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION AGS THERAPEUTICS SAS (FR) 2024-09-26 WO claimed
US-20260014092-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION AGS THERAPEUTICS SAS (FR) 2026-01-15 US disclosed
US-20240423923-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES AGS THERAPEUTICS SAS (FR) 2024-12-26 US disclosed
WO-2024194423-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION AGS THERAPEUTICS SAS (FR) 2024-09-26 WO disclosed
CN-117586108-A TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2024-02-23 CN disclosed
CN-117586191-A TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2024-02-23 CN disclosed
US-20230414678-A1 SHELF- STABLE AMMONIA OXIDIZING MICROORGANISM PREPARATIONS AOBIOME LLC (US) 2023-12-28 US disclosed
CN-111542515-B TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2023-12-05 CN disclosed
CN-116782924-A Storage-stable ammoxidation microbial preparation AO生物医学有限责任公司 2023-09-19 CN disclosed
US-20230201274-A1 SHELF- STABLE AMMONIA OXIDIZING MICROORGANISM PREPARATIONS AOBIOME LLC (US) 2023-06-29 US disclosed
US-20210179621-A1 Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2021-06-17 US disclosed
EP-0957918-A1 METHOD OF TREATING OR INHIBITING NEUTROPENIA American Cyanamid Company (US) 1999-11-24 EP disclosed
US-5932585-A Method of treating or inhibiting neutropenia AMERICAN CYANAMID COMPANY (US) 1999-08-03 US disclosed
WO-1998026781-A1 METHOD OF TREATING OR INHIBITING NEUTROPENIA AMERICAN CYANAMID COMPANY (US) 1998-06-25 WO disclosed
EP-0329940-B1 5-(substituted)amino)-8- (phenyl or substituted phenyl)-3H,6H-1,2,5,a,8 a-tetraazaacenaphthylen-3-ones AMERICAN CYANAMID CO (US) 1994-01-05 EP disclosed
US-5169850-A Neurotropic or hypotensive agents AMERICAN CYANAMID COMPANY (US) 1992-12-08 US disclosed
US-5059691-A Anxiolytic agents; hypotensive agents; nervous system disorders; cognition activators AMERICAN CYANAMID COMPANY (US) 1991-10-22 US disclosed
US-4916137-A 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders AMERICAN CYANAMID COMPANY (US) 1990-04-10 US disclosed
EP-0329940-A1 5-(substituted)amino)-8- (phenyl or substituted phenyl)-3H,6H-1,2,5,a,8 a-tetraazaacenaphthylen-3-ones AMERICAN CYANAMID COMPANY (US) 1989-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201274-A1 SHELF- STABLE AMMONIA OXIDIZING MICROORGANISM PREPARATIONS SI, OTC, APC TLR8 392/4885MAP2K1 4345/4885CLK4 4392/4885
US-20260014092-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION TLR9, TLR1, TLR2 TLR8 7/4885MAP2K1 2910/4885CLK4 1476/4885
US-20240423923-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON ADMINISTRATION, AND USES CHMP4B, ALG1, FUCA2 TLR8 654/4885MAP2K1 4456/4885CLK4 2225/4885
US-20210179621-A1 Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof TLR8, TLR3, TLR9 TLR8 1/4885MAP2K1 2248/4885CLK4 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.